4 Biotech Stocks That Could Keep Beating Wall Street
Some quick example text to build on the card title and make up the bulk of the card's content.
Go somewhere
object(stdClass)#3368 (10) {
["title"]=>
string(52) "4 Biotech Stocks That Could Keep Beating Wall Street"
["news_url"]=>
string(91) "http://www.zacks.com/stock/news/614227/4-biotech-stocks-that-could-keep-beating-wall-street"
["image_url"]=>
string(43) "https://cdn.snapi.dev/images/v1/5/9/594.jpg"
["text"]=>
string(148) "The biotechnology industry has lagged the broader market so far this year, but these four stocks have done pretty well and should continue to do so."
["sentiment"]=>
string(8) "Positive"
["type"]=>
string(7) "Article"
["source_name"]=>
string(25) "Zacks Investment Research"
["date"]=>
string(31) "Mon, 11 Nov 2019 09:28:00 -0500"
["tickers"]=>
array(4) {
[0]=>
string(4) "ACAD"
[1]=>
string(4) "CELG"
[2]=>
string(4) "CHRS"
[3]=>
string(4) "INCY"
}
["topics"]=>
array(0) {
}
}
Stocks Hold At Highs; Tesla, Acadia Break Out, JD.com Still A Buy
Some quick example text to build on the card title and make up the bulk of the card's content.
Go somewhere
object(stdClass)#3369 (10) {
["title"]=>
string(65) "Stocks Hold At Highs; Tesla, Acadia Break Out, JD.com Still A Buy"
["news_url"]=>
string(43) "https://www.youtube.com/watch?v=dDUEXznM8v8"
["image_url"]=>
string(48) "https://cdn.snapi.dev/images/v1/9/q/etf22-50.jpg"
["text"]=>
string(84) "Stocks hold at highs; Tesla, Acadia break out, JD.com still a buy after Singles Day."
["sentiment"]=>
string(8) "Positive"
["type"]=>
string(5) "Video"
["source_name"]=>
string(24) "Investors Business Daily"
["date"]=>
string(31) "Fri, 08 Nov 2019 16:08:08 -0500"
["tickers"]=>
array(3) {
[0]=>
string(2) "JD"
[1]=>
string(4) "TSLA"
[2]=>
string(4) "ACAD"
}
["topics"]=>
array(1) {
[0]=>
string(9) "tanalysis"
}
}
What Makes Acadia Pharmaceuticals (ACAD) a Strong Momentum Stock: Buy Now?
Some quick example text to build on the card title and make up the bulk of the card's content.
Go somewhere
object(stdClass)#3370 (10) {
["title"]=>
string(74) "What Makes Acadia Pharmaceuticals (ACAD) a Strong Momentum Stock: Buy Now?"
["news_url"]=>
string(109) "http://www.zacks.com/stock/news/606457/what-makes-acadia-pharmaceuticals-acad-a-strong-momentum-stock-buy-now"
["image_url"]=>
string(49) "https://cdn.snapi.dev/images/v1/s/t/biotech26.jpg"
["text"]=>
string(116) "Does Acadia Pharmaceuticals (ACAD) have what it takes to be a top stock pick for momentum investors? Let's find out."
["sentiment"]=>
string(8) "Positive"
["type"]=>
string(7) "Article"
["source_name"]=>
string(25) "Zacks Investment Research"
["date"]=>
string(31) "Wed, 06 Nov 2019 10:00:07 -0500"
["tickers"]=>
array(1) {
[0]=>
string(4) "ACAD"
}
["topics"]=>
array(0) {
}
}
Acadia (ACAD) Upgraded to Buy: Here's Why
Some quick example text to build on the card title and make up the bulk of the card's content.
Go somewhere
object(stdClass)#3371 (10) {
["title"]=>
string(41) "Acadia (ACAD) Upgraded to Buy: Here's Why"
["news_url"]=>
string(76) "http://www.zacks.com/stock/news/606282/acadia-acad-upgraded-to-buy-heres-why"
["image_url"]=>
string(49) "https://cdn.snapi.dev/images/v1/t/n/biotech20.jpg"
["text"]=>
string(141) "Acadia (ACAD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy)."
["sentiment"]=>
string(8) "Positive"
["type"]=>
string(7) "Article"
["source_name"]=>
string(25) "Zacks Investment Research"
["date"]=>
string(31) "Wed, 06 Nov 2019 09:00:06 -0500"
["tickers"]=>
array(1) {
[0]=>
string(4) "ACAD"
}
["topics"]=>
array(0) {
}
}
object(stdClass)#3372 (10) {
["title"]=>
string(42) "Is Acadia Pharmaceuticals Stock Now a Buy?"
["news_url"]=>
string(88) "https://www.fool.com/investing/2019/10/31/is-acadia-pharmaceuticals-stock-now-a-buy.aspx"
["image_url"]=>
string(49) "https://cdn.snapi.dev/images/v1/i/d/biotech14.jpg"
["text"]=>
string(83) "Acadia's shares shrugged off a stronger-than-expected Q3 earnings report yesterday."
["sentiment"]=>
string(8) "Positive"
["type"]=>
string(7) "Article"
["source_name"]=>
string(15) "The Motley Fool"
["date"]=>
string(31) "Thu, 31 Oct 2019 09:25:00 -0400"
["tickers"]=>
array(1) {
[0]=>
string(4) "ACAD"
}
["topics"]=>
array(0) {
}
}
object(stdClass)#3373 (10) {
["title"]=>
string(88) "Acadia Pharmaceuticals Delivers Record Q3 Revenue, Fueled by Antipsychotic Drug Nuplazid"
["news_url"]=>
string(96) "https://www.fool.com/investing/2019/10/31/acadia-pharmaceuticals-delivers-record-q3-revenue.aspx"
["image_url"]=>
string(146) "https://cdn.snapi.dev/images/v1/h/h/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5447462fgloved-hand-with-beaker-and-100-billsjpgw700opresize.jpg"
["text"]=>
string(125) "The biotech continues to enjoy great momentum for its only approved drug, with a big new FDA approval potentially on the way."
["sentiment"]=>
string(8) "Positive"
["type"]=>
string(7) "Article"
["source_name"]=>
string(15) "The Motley Fool"
["date"]=>
string(31) "Thu, 31 Oct 2019 06:00:00 -0400"
["tickers"]=>
array(1) {
[0]=>
string(4) "ACAD"
}
["topics"]=>
array(1) {
[0]=>
string(8) "earnings"
}
}
object(stdClass)#3374 (10) {
["title"]=>
string(96) "ACADIA Pharmaceuticals Inc. (ACAD) CEO Steve Davis on Q3 2019 Results - Earnings Call Transcript"
["news_url"]=>
string(129) "https://seekingalpha.com/article/4300699-acadia-pharmaceuticals-inc-acad-ceo-steve-davis-q3-2019-results-earnings-call-transcript"
["image_url"]=>
string(52) "https://cdn.snapi.dev/images/v1/w/b/transcript38.jpg"
["text"]=>
string(96) "ACADIA Pharmaceuticals Inc. (ACAD) CEO Steve Davis on Q3 2019 Results - Earnings Call Transcript"
["sentiment"]=>
string(7) "Neutral"
["type"]=>
string(7) "Article"
["source_name"]=>
string(13) "Seeking Alpha"
["date"]=>
string(31) "Wed, 30 Oct 2019 22:44:07 -0400"
["tickers"]=>
array(1) {
[0]=>
string(4) "ACAD"
}
["topics"]=>
array(1) {
[0]=>
string(10) "CallScript"
}
}
object(stdClass)#3375 (10) {
["title"]=>
string(69) "Acadia Pharmaceuticals (ACAD) Reports Q3 Loss, Tops Revenue Estimates"
["news_url"]=>
string(105) "http://www.zacks.com/stock/news/594122/acadia-pharmaceuticals-acad-reports-q3-loss-tops-revenue-estimates"
["image_url"]=>
string(49) "https://cdn.snapi.dev/images/v1/i/l/biotech36.jpg"
["text"]=>
string(187) "Acadia (ACAD) delivered earnings and revenue surprises of 29.27% and 6.79%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?"
["sentiment"]=>
string(7) "Neutral"
["type"]=>
string(7) "Article"
["source_name"]=>
string(25) "Zacks Investment Research"
["date"]=>
string(31) "Wed, 30 Oct 2019 19:25:07 -0400"
["tickers"]=>
array(1) {
[0]=>
string(4) "ACAD"
}
["topics"]=>
array(1) {
[0]=>
string(8) "earnings"
}
}
object(stdClass)#3376 (10) {
["title"]=>
string(58) "Will Nuplazid Aid Growth for ACADIA (ACAD) in Q3 Earnings?"
["news_url"]=>
string(94) "http://www.zacks.com/stock/news/584443/will-nuplazid-aid-growth-for-acadia-acad-in-q3-earnings"
["image_url"]=>
string(49) "https://cdn.snapi.dev/images/v1/j/e/biotech17.jpg"
["text"]=>
string(169) "During ACADIA's (ACAD) third-quarter 2019 conference call, investor focus will be on the sales figure of its only marketed drug Nuplazid and its label expansion studies."
["sentiment"]=>
string(8) "Positive"
["type"]=>
string(7) "Article"
["source_name"]=>
string(25) "Zacks Investment Research"
["date"]=>
string(31) "Fri, 25 Oct 2019 12:12:00 -0400"
["tickers"]=>
array(1) {
[0]=>
string(4) "ACAD"
}
["topics"]=>
array(1) {
[0]=>
string(8) "earnings"
}
}
object(stdClass)#3377 (10) {
["title"]=>
string(103) "Acadia Pharmaceuticals (ACAD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release"
["news_url"]=>
string(138) "http://www.zacks.com/stock/news/579051/acadia-pharmaceuticals-acad-may-report-negative-earnings-know-the-trend-ahead-of-next-weeks-release"
["image_url"]=>
string(48) "https://cdn.snapi.dev/images/v1/v/r/biotech4.jpg"
["text"]=>
string(169) "Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations."
["sentiment"]=>
string(8) "Negative"
["type"]=>
string(7) "Article"
["source_name"]=>
string(25) "Zacks Investment Research"
["date"]=>
string(31) "Wed, 23 Oct 2019 10:33:56 -0400"
["tickers"]=>
array(1) {
[0]=>
string(4) "ACAD"
}
["topics"]=>
array(1) {
[0]=>
string(8) "earnings"
}
}
object(stdClass)#3378 (10) {
["title"]=>
string(47) "3 Mid-Cap Biotech Stocks To Consider Buying Now"
["news_url"]=>
string(94) "https://www.fool.com/investing/2019/10/04/3-mid-cap-biotech-stocks-to-consider-buying-now.aspx"
["image_url"]=>
string(162) "https://cdn.snapi.dev/images/v1/e/y/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5414782fstock-quotes-on-digital-display-ticker-index-exchangejpgw700opresize.jpg"
["text"]=>
string(106) "These revenue-producing, possible acquisition candidates may be the right medicine to heal your portfolio."
["sentiment"]=>
string(8) "Positive"
["type"]=>
string(7) "Article"
["source_name"]=>
string(15) "The Motley Fool"
["date"]=>
string(31) "Fri, 04 Oct 2019 13:24:23 -0400"
["tickers"]=>
array(3) {
[0]=>
string(4) "ACAD"
[1]=>
string(4) "AMRN"
[2]=>
string(4) "EXEL"
}
["topics"]=>
array(0) {
}
}
object(stdClass)#3379 (10) {
["title"]=>
string(59) "Here's Why Acadia Pharmaceuticals Jumped 30.1% in September"
["news_url"]=>
string(97) "https://www.fool.com/investing/2019/10/04/heres-why-acadia-pharmaceuticals-jumped-301-in-sep.aspx"
["image_url"]=>
string(85) "https://cdn.snapi.dev/images/v1/a/6/105907193-1557515424687gettyimages-609179953.jpeg"
["text"]=>
string(61) "Unexpected phase 3 clinical trial data has investors smiling."
["sentiment"]=>
string(8) "Positive"
["type"]=>
string(7) "Article"
["source_name"]=>
string(15) "The Motley Fool"
["date"]=>
string(31) "Fri, 04 Oct 2019 10:08:00 -0400"
["tickers"]=>
array(1) {
[0]=>
string(4) "ACAD"
}
["topics"]=>
array(0) {
}
}
object(stdClass)#3380 (10) {
["title"]=>
string(37) "Acadia's Future Continues To Brighten"
["news_url"]=>
string(74) "https://seekingalpha.com/article/4293032-acadias-future-continues-brighten"
["image_url"]=>
string(48) "https://cdn.snapi.dev/images/v1/l/e/biotech2.jpg"
["text"]=>
string(59) "Acadia has released two positive data sets in recent weeks."
["sentiment"]=>
string(7) "Neutral"
["type"]=>
string(7) "Article"
["source_name"]=>
string(13) "Seeking Alpha"
["date"]=>
string(31) "Mon, 23 Sep 2019 12:36:51 -0400"
["tickers"]=>
array(1) {
[0]=>
string(4) "ACAD"
}
["topics"]=>
array(0) {
}
}
object(stdClass)#3381 (10) {
["title"]=>
string(67) "Notable Insider Buys In The Past Week: AbbVie, Kraft Heinz And More"
["news_url"]=>
string(110) "https://www.benzinga.com/news/19/09/14469210/notable-insider-buys-in-the-past-week-abbvie-kraft-heinz-and-more"
["image_url"]=>
string(64) "https://cdn.snapi.dev/images/v1/w/b/writing-1149962-1920-1-7.jpg"
["text"]=>
string(161) "Insider buying can be an encouraging signal for potential investors. A packaged food giant and two drugmakers saw notable insider buying activity this past week."
["sentiment"]=>
string(8) "Positive"
["type"]=>
string(7) "Article"
["source_name"]=>
string(8) "Benzinga"
["date"]=>
string(31) "Sun, 22 Sep 2019 17:00:14 -0400"
["tickers"]=>
array(4) {
[0]=>
string(4) "ABBV"
[1]=>
string(3) "KHC"
[2]=>
string(4) "ACAD"
[3]=>
string(4) "SGMS"
}
["topics"]=>
array(0) {
}
}
object(stdClass)#3382 (10) {
["title"]=>
string(38) "3 Biotech Stocks That Soared Last Week"
["news_url"]=>
string(85) "https://www.fool.com/investing/2019/09/15/3-biotech-stocks-that-soared-last-week.aspx"
["image_url"]=>
string(151) "https://cdn.snapi.dev/images/v1/w/r/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5397562fthree-thumbs-up-healthcare-providers-gettyjpgw700opresize.jpg"
["text"]=>
string(36) "How much longer can they keep it up?"
["sentiment"]=>
string(8) "Positive"
["type"]=>
string(7) "Article"
["source_name"]=>
string(15) "The Motley Fool"
["date"]=>
string(31) "Sun, 15 Sep 2019 11:38:00 -0400"
["tickers"]=>
array(3) {
[0]=>
string(4) "ACAD"
[1]=>
string(3) "KOD"
[2]=>
string(4) "MESO"
}
["topics"]=>
array(0) {
}
}
object(stdClass)#3383 (10) {
["title"]=>
string(93) "Acadia Battles Back With Latest Nuplazid Data As Trial Is Stopped Early On Successful Finding"
["news_url"]=>
string(120) "https://seekingalpha.com/article/4291311-acadia-battles-back-latest-nuplazid-data-trial-stopped-early-successful-finding"
["image_url"]=>
string(49) "https://cdn.snapi.dev/images/v1/i/8/biotech38.jpg"
["text"]=>
string(176) "Acadia announced that its phase 3 study using Nuplazid to treat patients with dementia-related psychosis was stopped early after the IDMC concluded that the study goal was met."
["sentiment"]=>
string(8) "Positive"
["type"]=>
string(7) "Article"
["source_name"]=>
string(13) "Seeking Alpha"
["date"]=>
string(31) "Thu, 12 Sep 2019 23:19:41 -0400"
["tickers"]=>
array(1) {
[0]=>
string(4) "ACAD"
}
["topics"]=>
array(0) {
}
}
object(stdClass)#3384 (10) {
["title"]=>
string(50) "Does Acadia Pharmaceuticals Have More Room to Run?"
["news_url"]=>
string(96) "https://www.fool.com/investing/2019/09/11/does-acadia-pharmaceuticals-have-more-room-to-run.aspx"
["image_url"]=>
string(49) "https://cdn.snapi.dev/images/v1/j/5/biotech29.jpg"
["text"]=>
string(42) "Acadia's stock has taken flight this year."
["sentiment"]=>
string(8) "Positive"
["type"]=>
string(7) "Article"
["source_name"]=>
string(15) "The Motley Fool"
["date"]=>
string(31) "Wed, 11 Sep 2019 10:44:00 -0400"
["tickers"]=>
array(1) {
[0]=>
string(4) "ACAD"
}
["topics"]=>
array(0) {
}
}
object(stdClass)#3385 (10) {
["title"]=>
string(103) "'Pleasantly Surprised' Acadia Analysts See Blockbuster Potential For Pimavanserin In Dementia Psychosis"
["news_url"]=>
string(153) "https://www.benzinga.com/analyst-ratings/analyst-color/19/09/14407503/pleasantly-surprised-acadia-analysts-see-blockbuster-potential-for-pimavanserin-in-"
["image_url"]=>
string(61) "https://cdn.snapi.dev/images/v1/o/n/brain-1787622-1920-19.jpg"
["text"]=>
string(206) "ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) shares, which rallied over 63% Monday following positive results from its pimavanserin in dementia-related psychosis, were seeing further upward momentum Tuesday."
["sentiment"]=>
string(8) "Positive"
["type"]=>
string(7) "Article"
["source_name"]=>
string(8) "Benzinga"
["date"]=>
string(31) "Tue, 10 Sep 2019 13:20:40 -0400"
["tickers"]=>
array(1) {
[0]=>
string(4) "ACAD"
}
["topics"]=>
array(0) {
}
}
object(stdClass)#3386 (10) {
["title"]=>
string(57) "ACADIA Surges on Early Success of Nuplazid Dementia Study"
["news_url"]=>
string(96) "http://www.zacks.com/stock/news/511373/acadia-surges-on-early-success-of-nuplazid-dementia-study"
["image_url"]=>
string(49) "https://cdn.snapi.dev/images/v1/g/w/biotech35.jpg"
["text"]=>
string(208) "ACADIA Pharmaceuticals' (ACAD) Parkinson's psychosis drug, Nuplazid, meets primary endpoint earlier than expected in late-stage label expansion study evaluating it in patients with dementia-related psychosis."
["sentiment"]=>
string(8) "Positive"
["type"]=>
string(7) "Article"
["source_name"]=>
string(25) "Zacks Investment Research"
["date"]=>
string(31) "Tue, 10 Sep 2019 11:41:00 -0400"
["tickers"]=>
array(1) {
[0]=>
string(4) "ACAD"
}
["topics"]=>
array(0) {
}
}
object(stdClass)#3387 (10) {
["title"]=>
string(37) "Will ACADIA Continue to Surge Higher?"
["news_url"]=>
string(75) "http://www.zacks.com/stock/news/511273/will-acadia-continue-to-surge-higher"
["image_url"]=>
string(48) "https://cdn.snapi.dev/images/v1/1/h/biotech1.jpg"
["text"]=>
string(89) "As of late, it has definitely been a great time to be an investor ACADIA Pharmaceuticals."
["sentiment"]=>
string(8) "Positive"
["type"]=>
string(7) "Article"
["source_name"]=>
string(25) "Zacks Investment Research"
["date"]=>
string(31) "Tue, 10 Sep 2019 10:59:00 -0400"
["tickers"]=>
array(1) {
[0]=>
string(4) "ACAD"
}
["topics"]=>
array(0) {
}
}
object(stdClass)#3388 (10) {
["title"]=>
string(58) "Is Acadia Pharmaceuticals a Good Biotech Stock to Buy Now?"
["news_url"]=>
string(96) "https://www.fool.com/investing/2019/09/10/is-acadia-pharmaceuticals-a-good-biotech-stock-to.aspx"
["image_url"]=>
string(50) "https://cdn.snapi.dev/images/v1/3/w/biotech6-3.jpg"
["text"]=>
string(65) "Lackluster sales of Nuplazid could finally take flight next year."
["sentiment"]=>
string(8) "Positive"
["type"]=>
string(7) "Article"
["source_name"]=>
string(15) "The Motley Fool"
["date"]=>
string(31) "Tue, 10 Sep 2019 08:39:00 -0400"
["tickers"]=>
array(1) {
[0]=>
string(4) "ACAD"
}
["topics"]=>
array(0) {
}
}
object(stdClass)#3389 (10) {
["title"]=>
string(50) "Why Acadia Pharmaceuticals Stock Skyrocketed Today"
["news_url"]=>
string(97) "https://www.fool.com/investing/2019/09/09/why-acadia-pharmaceuticals-stock-skyrocketed-today.aspx"
["image_url"]=>
string(111) "https://cdn.snapi.dev/images/v1/c/o/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5392202fadjpgw700opresize.jpg"
["text"]=>
string(58) "Acadia's flagship drug notched a key late-stage win today."
["sentiment"]=>
string(8) "Positive"
["type"]=>
string(7) "Article"
["source_name"]=>
string(15) "The Motley Fool"
["date"]=>
string(31) "Mon, 09 Sep 2019 17:38:00 -0400"
["tickers"]=>
array(1) {
[0]=>
string(4) "ACAD"
}
["topics"]=>
array(0) {
}
}
object(stdClass)#3390 (10) {
["title"]=>
string(114) "Acadia Stops Nuplazid Study Early After Drug Shows 'Statistically Superior Efficacy' In Dementia-Related Psychosis"
["news_url"]=>
string(153) "https://www.benzinga.com/general/biotech/19/09/14399015/acadia-stops-nuplazid-study-early-after-drug-shows-statistically-superior-efficacy-in-dementia-re"
["image_url"]=>
string(64) "https://cdn.snapi.dev/images/v1/s/y/syringe-1884784-1920-1-5.jpg"
["text"]=>
string(156) "ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) shares are soaring to their highest level in about two years following a clinical trial readout from the company."
["sentiment"]=>
string(8) "Positive"
["type"]=>
string(7) "Article"
["source_name"]=>
string(8) "Benzinga"
["date"]=>
string(31) "Mon, 09 Sep 2019 14:33:33 -0400"
["tickers"]=>
array(1) {
[0]=>
string(4) "ACAD"
}
["topics"]=>
array(0) {
}
}
object(stdClass)#3391 (10) {
["title"]=>
string(63) "Why This Small Biotech Stock Just Rocketed 74% To A 3-Year High"
["news_url"]=>
string(106) "https://www.investors.com/news/technology/acadia-stock-rockets-psychosis-treatment-proves-itself-dementia/"
["image_url"]=>
string(49) "https://cdn.snapi.dev/images/v1/b/i/biotech18.jpg"
["text"]=>
string(187) "Shares of Acadia Pharmaceuticals rocketed Monday after the biotech company said its psychosis treatment met its key goal in a Phase 3 test. The drug already sells under the name Nuplazid."
["sentiment"]=>
string(8) "Positive"
["type"]=>
string(7) "Article"
["source_name"]=>
string(24) "Investors Business Daily"
["date"]=>
string(31) "Mon, 09 Sep 2019 09:42:30 -0400"
["tickers"]=>
array(1) {
[0]=>
string(4) "ACAD"
}
["topics"]=>
array(0) {
}
}
object(stdClass)#3418 (10) {
["title"]=>
string(32) "ACADIA Enters Oversold Territory"
["news_url"]=>
string(71) "http://www.zacks.com/stock/news/509202/acadia-enters-oversold-territory"
["image_url"]=>
string(48) "https://cdn.snapi.dev/images/v1/s/q/biotech6.jpg"
["text"]=>
string(142) "ACADIA Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock."
["sentiment"]=>
string(8) "Positive"
["type"]=>
string(7) "Article"
["source_name"]=>
string(25) "Zacks Investment Research"
["date"]=>
string(31) "Mon, 09 Sep 2019 09:05:00 -0400"
["tickers"]=>
array(1) {
[0]=>
string(4) "ACAD"
}
["topics"]=>
array(0) {
}
}
object(stdClass)#3417 (10) {
["title"]=>
string(97) "Acadia Pharmaceuticals stock rockets after late-stage trial of pimavanserin mets primary endpoint"
["news_url"]=>
string(142) "https://www.marketwatch.com/story/acadia-pharmaceuticals-stock-rockets-after-late-stage-trial-of-pimavanserin-mets-primary-endpoint-2019-09-09"
["image_url"]=>
string(48) "https://cdn.snapi.dev/images/v1/i/4/biotech4.jpg"
["text"]=>
string(244) "Shares of Acadia Pharmaceuticals Inc. ACAD, -2.94% rocketed 87% toward a 4-year high in premarket trading Monday, after the biopharmaceutical company said a phase 3 trial of its treatment for dementia-related psychosis met its primary endpoint."
["sentiment"]=>
string(8) "Positive"
["type"]=>
string(7) "Article"
["source_name"]=>
string(12) "Market Watch"
["date"]=>
string(31) "Mon, 09 Sep 2019 07:26:31 -0400"
["tickers"]=>
array(1) {
[0]=>
string(4) "ACAD"
}
["topics"]=>
array(0) {
}
}
object(stdClass)#3416 (10) {
["title"]=>
string(49) "Top Ranked Momentum Stocks to Buy for August 29th"
["news_url"]=>
string(88) "http://www.zacks.com/commentary/494499/top-ranked-momentum-stocks-to-buy-for-august-29th"
["image_url"]=>
string(58) "https://cdn.snapi.dev/images/v1/a/s/asset-management31.jpg"
["text"]=>
string(49) "Top Ranked Momentum Stocks to Buy for August 29th"
["sentiment"]=>
string(8) "Positive"
["type"]=>
string(7) "Article"
["source_name"]=>
string(25) "Zacks Investment Research"
["date"]=>
string(31) "Thu, 29 Aug 2019 12:47:00 -0400"
["tickers"]=>
array(4) {
[0]=>
string(4) "ACAD"
[1]=>
string(3) "CVS"
[2]=>
string(3) "GMS"
[3]=>
string(2) "PG"
}
["topics"]=>
array(0) {
}
}
object(stdClass)#3415 (10) {
["title"]=>
string(49) "Top Ranked Momentum Stocks to Buy for August 26th"
["news_url"]=>
string(88) "http://www.zacks.com/commentary/489130/top-ranked-momentum-stocks-to-buy-for-august-26th"
["image_url"]=>
string(58) "https://cdn.snapi.dev/images/v1/o/i/arbor-realty-trust.jpg"
["text"]=>
string(49) "Top Ranked Momentum Stocks to Buy for August 26th"
["sentiment"]=>
string(8) "Positive"
["type"]=>
string(7) "Article"
["source_name"]=>
string(25) "Zacks Investment Research"
["date"]=>
string(31) "Mon, 26 Aug 2019 08:39:00 -0400"
["tickers"]=>
array(4) {
[0]=>
string(3) "ABR"
[1]=>
string(4) "ACAD"
[2]=>
string(4) "AMGN"
[3]=>
string(3) "AUY"
}
["topics"]=>
array(0) {
}
}
object(stdClass)#3414 (10) {
["title"]=>
string(49) "Top Ranked Momentum Stocks to Buy for August 23rd"
["news_url"]=>
string(88) "http://www.zacks.com/commentary/484850/top-ranked-momentum-stocks-to-buy-for-august-23rd"
["image_url"]=>
string(45) "https://cdn.snapi.dev/images/v1/e/t/etf15.jpg"
["text"]=>
string(49) "Top Ranked Momentum Stocks to Buy for August 23rd"
["sentiment"]=>
string(8) "Positive"
["type"]=>
string(7) "Article"
["source_name"]=>
string(25) "Zacks Investment Research"
["date"]=>
string(31) "Fri, 23 Aug 2019 11:44:00 -0400"
["tickers"]=>
array(3) {
[0]=>
string(3) "ABC"
[1]=>
string(4) "ACAD"
[2]=>
string(3) "AER"
}
["topics"]=>
array(0) {
}
}
object(stdClass)#3413 (10) {
["title"]=>
string(49) "Top Ranked Momentum Stocks to Buy for August 15th"
["news_url"]=>
string(88) "http://www.zacks.com/commentary/471893/top-ranked-momentum-stocks-to-buy-for-august-15th"
["image_url"]=>
string(44) "https://cdn.snapi.dev/images/v1/e/t/etf3.jpg"
["text"]=>
string(49) "Top Ranked Momentum Stocks to Buy for August 15th"
["sentiment"]=>
string(8) "Positive"
["type"]=>
string(7) "Article"
["source_name"]=>
string(25) "Zacks Investment Research"
["date"]=>
string(31) "Thu, 15 Aug 2019 09:43:00 -0400"
["tickers"]=>
array(3) {
[0]=>
string(4) "ACAD"
[1]=>
string(4) "AOSL"
[2]=>
string(4) "APPS"
}
["topics"]=>
array(0) {
}
}
object(stdClass)#3412 (10) {
["title"]=>
string(49) "Top Ranked Momentum Stocks to Buy for August 14th"
["news_url"]=>
string(88) "http://www.zacks.com/commentary/470346/top-ranked-momentum-stocks-to-buy-for-august-14th"
["image_url"]=>
string(68) "https://cdn.snapi.dev/images/v1/1/4/14498884-stock-market-graphs.jpg"
["text"]=>
string(116) "Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 14th:"
["sentiment"]=>
string(8) "Positive"
["type"]=>
string(7) "Article"
["source_name"]=>
string(25) "Zacks Investment Research"
["date"]=>
string(31) "Wed, 14 Aug 2019 11:09:00 -0400"
["tickers"]=>
array(4) {
[0]=>
string(4) "ACAD"
[1]=>
string(3) "AER"
[2]=>
string(4) "AJRD"
[3]=>
string(3) "BUD"
}
["topics"]=>
array(0) {
}
}
object(stdClass)#3411 (10) {
["title"]=>
string(49) "Top Ranked Momentum Stocks to Buy for August 12th"
["news_url"]=>
string(88) "http://www.zacks.com/commentary/466759/top-ranked-momentum-stocks-to-buy-for-august-12th"
["image_url"]=>
string(50) "https://cdn.snapi.dev/images/v1/1/5/1544783938.jpg"
["text"]=>
string(49) "Top Ranked Momentum Stocks to Buy for August 12th"
["sentiment"]=>
string(8) "Positive"
["type"]=>
string(7) "Article"
["source_name"]=>
string(25) "Zacks Investment Research"
["date"]=>
string(31) "Mon, 12 Aug 2019 09:09:00 -0400"
["tickers"]=>
array(4) {
[0]=>
string(4) "ACAD"
[1]=>
string(3) "AER"
[2]=>
string(3) "AGI"
[3]=>
string(4) "BIIB"
}
["topics"]=>
array(0) {
}
}
object(stdClass)#3410 (10) {
["title"]=>
string(72) "ACADIA Pharmaceuticals Inc. (ACAD) Shares March Higher, Can It Continue?"
["news_url"]=>
string(106) "http://www.zacks.com/stock/news/459573/acadia-pharmaceuticals-inc-acad-shares-march-higher-can-it-continue"
["image_url"]=>
string(49) "https://cdn.snapi.dev/images/v1/t/g/biotech10.jpg"
["text"]=>
string(104) "As of late, it has definitely been a great time to be an investor in ACADIA Pharmaceuticals Inc. (ACAD)."
["sentiment"]=>
string(8) "Positive"
["type"]=>
string(7) "Article"
["source_name"]=>
string(25) "Zacks Investment Research"
["date"]=>
string(31) "Tue, 06 Aug 2019 08:08:00 -0400"
["tickers"]=>
array(1) {
[0]=>
string(4) "ACAD"
}
["topics"]=>
array(0) {
}
}
object(stdClass)#3331 (10) {
["title"]=>
string(53) "Why Acadia Pharmaceuticals Stock Is Crushing It Today"
["news_url"]=>
string(97) "https://www.fool.com/investing/2019/08/01/why-acadia-pharmaceuticals-stock-is-crushing-it-to.aspx"
["image_url"]=>
string(51) "https://cdn.snapi.dev/images/v1/b/i/biotech18-8.jpg"
["text"]=>
string(100) "Great Q2 results powered by strong momentum for antipsychotic drug Nuplazid have investors fired up."
["sentiment"]=>
string(8) "Positive"
["type"]=>
string(7) "Article"
["source_name"]=>
string(15) "The Motley Fool"
["date"]=>
string(31) "Thu, 01 Aug 2019 12:06:06 -0400"
["tickers"]=>
array(1) {
[0]=>
string(4) "ACAD"
}
["topics"]=>
array(0) {
}
}
object(stdClass)#3301 (10) {
["title"]=>
string(47) "Acadia Pharmaceuticals Beats Expectations in Q2"
["news_url"]=>
string(94) "https://www.fool.com/investing/2019/08/01/acadia-pharmaceuticals-beats-expectations-in-q2.aspx"
["image_url"]=>
string(132) "https://cdn.snapi.dev/images/v1/m/s/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5338022ftest-tubes-with-dropperjpgw700opresize.jpg"
["text"]=>
string(100) "Nuplazid picked up momentum in the second quarter, enabling Acadia to up its full-year 2019 outlook."
["sentiment"]=>
string(8) "Positive"
["type"]=>
string(7) "Article"
["source_name"]=>
string(15) "The Motley Fool"
["date"]=>
string(31) "Thu, 01 Aug 2019 06:00:00 -0400"
["tickers"]=>
array(1) {
[0]=>
string(4) "ACAD"
}
["topics"]=>
array(1) {
[0]=>
string(8) "earnings"
}
}
object(stdClass)#3302 (10) {
["title"]=>
string(96) "ACADIA Pharmaceuticals Inc. (ACAD) CEO Steve Davis on Q2 2019 Results - Earnings Call Transcript"
["news_url"]=>
string(160) "https://seekingalpha.com/article/4279899-acadia-pharmaceuticals-inc-acad-ceo-steve-davis-q2-2019-results-earnings-call-transcript?source=feed_sector_transcripts"
["image_url"]=>
string(52) "https://cdn.snapi.dev/images/v1/a/q/transcript48.jpg"
["text"]=>
string(96) "ACADIA Pharmaceuticals Inc. (ACAD) CEO Steve Davis on Q2 2019 Results - Earnings Call Transcript"
["sentiment"]=>
string(7) "Neutral"
["type"]=>
string(7) "Article"
["source_name"]=>
string(13) "Seeking Alpha"
["date"]=>
string(31) "Wed, 31 Jul 2019 22:35:19 -0400"
["tickers"]=>
array(1) {
[0]=>
string(4) "ACAD"
}
["topics"]=>
array(1) {
[0]=>
string(10) "CallScript"
}
}
object(stdClass)#3303 (10) {
["title"]=>
string(69) "Acadia Pharmaceuticals (ACAD) Reports Q2 Loss, Tops Revenue Estimates"
["news_url"]=>
string(105) "http://www.zacks.com/stock/news/455360/acadia-pharmaceuticals-acad-reports-q2-loss-tops-revenue-estimates"
["image_url"]=>
string(49) "https://cdn.snapi.dev/images/v1/g/g/biotech26.jpg"
["text"]=>
string(183) "Acadia (ACAD) delivered earnings and revenue surprises of 17.39% and 13.86%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?"
["sentiment"]=>
string(8) "Positive"
["type"]=>
string(7) "Article"
["source_name"]=>
string(25) "Zacks Investment Research"
["date"]=>
string(31) "Wed, 31 Jul 2019 18:55:07 -0400"
["tickers"]=>
array(1) {
[0]=>
string(4) "ACAD"
}
["topics"]=>
array(1) {
[0]=>
string(8) "earnings"
}
}
object(stdClass)#3304 (10) {
["title"]=>
string(80) "Acadia May Have Lost The Battle In Its Phase 3 Study, But A Path Forward Remains"
["news_url"]=>
string(125) "https://seekingalpha.com/article/4279520-acadia-may-lost-battle-phase-3-study-path-forward-remains?source=feed_tag_long_ideas"
["image_url"]=>
string(49) "https://cdn.snapi.dev/images/v1/z/z/biotech14.jpg"
["text"]=>
string(127) "Acadia fails to meet primary endpoint in Phase 3 study with pimavanserin as an adjunct treatment for adults with schizophrenia."
["sentiment"]=>
string(8) "Negative"
["type"]=>
string(7) "Article"
["source_name"]=>
string(13) "Seeking Alpha"
["date"]=>
string(31) "Wed, 31 Jul 2019 11:42:44 -0400"
["tickers"]=>
array(1) {
[0]=>
string(4) "ACAD"
}
["topics"]=>
array(0) {
}
}
object(stdClass)#3305 (10) {
["title"]=>
string(91) "Will Acadia Pharmaceuticals (ACAD) Report Negative Earnings Next Week? What You Should Know"
["news_url"]=>
string(127) "http://www.zacks.com/stock/news/448646/will-acadia-pharmaceuticals-acad-report-negative-earnings-next-week-what-you-should-know"
["image_url"]=>
string(49) "https://cdn.snapi.dev/images/v1/j/q/biotech29.jpg"
["text"]=>
string(169) "Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations."
["sentiment"]=>
string(8) "Negative"
["type"]=>
string(7) "Article"
["source_name"]=>
string(25) "Zacks Investment Research"
["date"]=>
string(31) "Wed, 24 Jul 2019 10:32:30 -0400"
["tickers"]=>
array(1) {
[0]=>
string(4) "ACAD"
}
["topics"]=>
array(1) {
[0]=>
string(8) "earnings"
}
}
object(stdClass)#3306 (10) {
["title"]=>
string(54) "Is Acadia Pharma’s Schizophrenia Treatment Done For?"
["news_url"]=>
string(104) "https://247wallst.com/healthcare-business/2019/07/23/is-acadia-pharmas-schizophrenia-treatment-done-for/"
["image_url"]=>
string(51) "https://cdn.snapi.dev/images/v1/b/i/biotech27-9.jpg"
["text"]=>
string(253) "Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) shares dropped on Tuesday after the firm announced results from its late-stage study for the treatment of adult schizophrenia patients with persistent inadequate response to their current antipsychotic therapy."
["sentiment"]=>
string(8) "Negative"
["type"]=>
string(7) "Article"
["source_name"]=>
string(16) "24/7 Wall Street"
["date"]=>
string(31) "Tue, 23 Jul 2019 12:05:31 -0400"
["tickers"]=>
array(1) {
[0]=>
string(4) "ACAD"
}
["topics"]=>
array(0) {
}
}
object(stdClass)#3307 (10) {
["title"]=>
string(43) "Why Acadia Pharmaceuticals Is Tanking Today"
["news_url"]=>
string(90) "https://www.fool.com/investing/2019/07/23/why-acadia-pharmaceuticals-is-tanking-today.aspx"
["image_url"]=>
string(51) "https://cdn.snapi.dev/images/v1/b/i/biotech10-6.jpg"
["text"]=>
string(63) "Shares slump after the drugmaker releases bummer clinical news."
["sentiment"]=>
string(8) "Negative"
["type"]=>
string(7) "Article"
["source_name"]=>
string(15) "The Motley Fool"
["date"]=>
string(31) "Tue, 23 Jul 2019 11:38:00 -0400"
["tickers"]=>
array(1) {
[0]=>
string(4) "ACAD"
}
["topics"]=>
array(0) {
}
}
object(stdClass)#3310 (10) {
["title"]=>
string(52) "Are These 2 Beaten-Down Biotech Stocks Worth Buying?"
["news_url"]=>
string(97) "https://www.fool.com/investing/2019/07/23/are-these-2-beaten-down-biotech-stocks-worth-buyin.aspx"
["image_url"]=>
string(49) "https://cdn.snapi.dev/images/v1/v/a/va-jan-31.jpg"
["text"]=>
string(72) "Acadia Pharmaceuticals and Dynavax Technologies are having a rough week."
["sentiment"]=>
string(7) "Neutral"
["type"]=>
string(7) "Article"
["source_name"]=>
string(15) "The Motley Fool"
["date"]=>
string(31) "Tue, 23 Jul 2019 11:00:00 -0400"
["tickers"]=>
array(2) {
[0]=>
string(4) "ACAD"
[1]=>
string(4) "DVAX"
}
["topics"]=>
array(0) {
}
}
object(stdClass)#3327 (10) {
["title"]=>
string(77) "Acadia's schizophrenia treatment misses late-stage main goal; shares tank 16%"
["news_url"]=>
string(118) "https://www.cnbc.com/2019/07/23/acadias-schizophrenia-treatment-misses-late-stage-main-goal-shares-tank-16percent.html"
["image_url"]=>
string(87) "https://cdn.snapi.dev/images/v1/1/0-3/105907193-1557515424687gettyimages-609179953.jpeg"
["text"]=>
string(118) "Acadia Pharmaceuticals said its add-on treatment for schizophrenia failed to meet the main goal in a late-stage study."
["sentiment"]=>
string(8) "Negative"
["type"]=>
string(7) "Article"
["source_name"]=>
string(4) "CNBC"
["date"]=>
string(31) "Tue, 23 Jul 2019 06:28:00 -0400"
["tickers"]=>
array(1) {
[0]=>
string(4) "ACAD"
}
["topics"]=>
array(0) {
}
}
object(stdClass)#3311 (10) {
["title"]=>
string(68) "Acadia stock drops as schizophrenia drug doesn't pass clinical trial"
["news_url"]=>
string(112) "https://www.marketwatch.com/story/acadia-stock-drops-as-schizophrenia-drug-doesnt-pass-clinical-trial-2019-07-22"
["image_url"]=>
string(51) "https://cdn.snapi.dev/images/v1/b/i/biotech12-5.jpg"
["text"]=>
string(177) "Acadia Pharmaceuticals Inc. shares dropped in the extended session Monday after the biotech drug maker said its schizophrenia treatment did not pass a late-stage clinical trial."
["sentiment"]=>
string(8) "Negative"
["type"]=>
string(7) "Article"
["source_name"]=>
string(12) "Market Watch"
["date"]=>
string(31) "Mon, 22 Jul 2019 16:53:38 -0400"
["tickers"]=>
array(1) {
[0]=>
string(4) "ACAD"
}
["topics"]=>
array(0) {
}
}
object(stdClass)#3409 (10) {
["title"]=>
string(49) "Why Acadia Pharmaceuticals Stock Slumped in April"
["news_url"]=>
string(117) "https://www.fool.com/investing/2019/05/08/why-acadia-pharmaceuticals-inc-slumped-in-april.aspx?source=iedfolrf0000001"
["image_url"]=>
string(50) "https://cdn.snapi.dev/images/v1/b/i/biotech6-3.jpg"
["text"]=>
string(89) "The contentious drug-pricing debate weighed on Acadia Pharmaceuticals' shares last month."
["sentiment"]=>
string(8) "Negative"
["type"]=>
string(7) "Article"
["source_name"]=>
string(15) "The Motley Fool"
["date"]=>
string(31) "Wed, 08 May 2019 15:30:00 -0400"
["tickers"]=>
array(1) {
[0]=>
string(4) "ACAD"
}
["topics"]=>
array(0) {
}
}
object(stdClass)#3401 (10) {
["title"]=>
string(27) "Acadia: Cascading Catalysts"
["news_url"]=>
string(94) "https://seekingalpha.com/article/4260399-acadia-cascading-catalysts?source=feed_tag_long_ideas"
["image_url"]=>
string(49) "https://cdn.snapi.dev/images/v1/w/h/biotech35.jpg"
["text"]=>
string(135) "Acadia's existing revenue trajectory from its FDA approved Nuplazid therapy is growing nicely but requires significant supplementation."
["sentiment"]=>
string(8) "Positive"
["type"]=>
string(7) "Article"
["source_name"]=>
string(13) "Seeking Alpha"
["date"]=>
string(31) "Mon, 06 May 2019 05:43:49 -0400"
["tickers"]=>
array(1) {
[0]=>
string(4) "ACAD"
}
["topics"]=>
array(0) {
}
}
object(stdClass)#3402 (10) {
["title"]=>
string(96) "ACADIA Pharmaceuticals Inc. (ACAD) CEO Steve Davis on Q1 2019 Results - Earnings Call Transcript"
["news_url"]=>
string(160) "https://seekingalpha.com/article/4259448-acadia-pharmaceuticals-inc-acad-ceo-steve-davis-q1-2019-results-earnings-call-transcript?source=feed_sector_transcripts"
["image_url"]=>
string(52) "https://cdn.snapi.dev/images/v1/h/9/transcript19.jpg"
["text"]=>
string(96) "ACADIA Pharmaceuticals Inc. (ACAD) CEO Steve Davis on Q1 2019 Results - Earnings Call Transcript"
["sentiment"]=>
string(7) "Neutral"
["type"]=>
string(7) "Article"
["source_name"]=>
string(13) "Seeking Alpha"
["date"]=>
string(31) "Fri, 03 May 2019 00:05:07 -0400"
["tickers"]=>
array(1) {
[0]=>
string(4) "ACAD"
}
["topics"]=>
array(1) {
[0]=>
string(10) "CallScript"
}
}
object(stdClass)#3403 (10) {
["title"]=>
string(69) "Acadia Pharmaceuticals (ACAD) Reports Q1 Loss, Tops Revenue Estimates"
["news_url"]=>
string(105) "http://www.zacks.com/stock/news/407008/acadia-pharmaceuticals-acad-reports-q1-loss-tops-revenue-estimates"
["image_url"]=>
string(48) "https://cdn.snapi.dev/images/v1/y/d/biotech5.jpg"
["text"]=>
string(183) "Acadia (ACAD) delivered earnings and revenue surprises of -9.26% and 6.17%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?"
["sentiment"]=>
string(8) "Positive"
["type"]=>
string(7) "Article"
["source_name"]=>
string(25) "Zacks Investment Research"
["date"]=>
string(31) "Wed, 01 May 2019 19:35:06 -0400"
["tickers"]=>
array(1) {
[0]=>
string(4) "ACAD"
}
["topics"]=>
array(1) {
[0]=>
string(8) "earnings"
}
}
object(stdClass)#3404 (10) {
["title"]=>
string(47) "Acadia Adds Catalysts As More Readouts Approach"
["news_url"]=>
string(107) "https://seekingalpha.com/article/4257391-acadia-adds-catalysts-readouts-approach?source=feed_tag_long_ideas"
["image_url"]=>
string(49) "https://cdn.snapi.dev/images/v1/y/7/biotech30.jpg"
["text"]=>
string(53) "ACAD has initiated two phase 3 studies in depression."
["sentiment"]=>
string(8) "Positive"
["type"]=>
string(7) "Article"
["source_name"]=>
string(13) "Seeking Alpha"
["date"]=>
string(31) "Sat, 27 Apr 2019 09:30:04 -0400"
["tickers"]=>
array(1) {
[0]=>
string(4) "ACAD"
}
["topics"]=>
array(0) {
}
}
object(stdClass)#3405 (10) {
["title"]=>
string(101) "Analysts Estimate Acadia Pharmaceuticals (ACAD) to Report a Decline in Earnings: What to Look Out for"
["news_url"]=>
string(137) "http://www.zacks.com/stock/news/394767/analysts-estimate-acadia-pharmaceuticals-acad-to-report-a-decline-in-earnings-what-to-look-out-for"
["image_url"]=>
string(48) "https://cdn.snapi.dev/images/v1/h/4/biotech5.jpg"
["text"]=>
string(169) "Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations."
["sentiment"]=>
string(8) "Negative"
["type"]=>
string(7) "Article"
["source_name"]=>
string(25) "Zacks Investment Research"
["date"]=>
string(31) "Wed, 24 Apr 2019 10:33:51 -0400"
["tickers"]=>
array(1) {
[0]=>
string(4) "ACAD"
}
["topics"]=>
array(1) {
[0]=>
string(8) "earnings"
}
}
the numer of count is
50
